Search This Blog

Monday, December 8, 2025

AMA Faces Federal Scrutiny Over CPT Code Revenue

 A physician-turned-prominent senator has put the American Medical Association (AMA) on notice again, demanding an accounting of the profits it earns from its “monopoly” over the coding system used for provider reimbursement.

The letter from Republican Senator Bill Cassidy, MD, chair of the Senate Health, Education, Labor, and Pensions Committee, is the latest push to understand how the nation’s leading physician organization maintains control over the Current Procedural Terminology (CPT) system. Hospitals and clinicians must license the more than 11,000 CPT codes to bill and operate, and they pay annual royalties for that access. Provider reimbursement rates are also tied to the code set.

The inquiry follows an announcement from the Centers for Medicare and Medicaid Services (CMS) of an upcoming 2.5% “efficiency” cut to physician payments, adding to concerns about how provider reimbursements are calculated.

An AMA official who declined to speak on the record told Medscape Medical News that the organization has received Cassidy’s letter and plans to respond.

Here’s what you need to know about the request.

1. How Code Became National Standard

The AMA published the first CPT code set in 1966 to standardize terms and descriptions in medical documentation and insurer communications. While the first edition focused primarily on surgical procedures, the second edition in 1970 expanded to include other specialties, and subsequent versions have added codes as medicine has advanced.

However, a series of federal legislative changes in the 1980s strengthened CPT’s role in provider reimbursement. CMS first adopted the CPT framework in 1983 as part of its Healthcare Common Procedure Coding System for reporting Part B Medicare services. Three years later, the agency extended the requirement to Medicaid programs.

But the passage of the Health Insurance Portability and Accountability Act a decade later cemented CPT codes’ status by designating them the national standard for physician and provider billing. CMS, with input from an AMA advisory committee, assigns each code a relative value unit (RVU) that determines reimbursement. Private payers typically base their payments on similar rates.

2. Panel Oversees Code, Updates

While the AMA owns the code set copyright, oversight falls to the organization’s CPT Editorial Panel. The 21-member group is “broadly representative of physicians and other stakeholders,” including 12 seats appointed by national medical specialist groups, John Whyte, MD, MPH, CEO and executive vice president of the AMA, explained in response to Cassidy’s October probe. Other members come from the CPT Health Care Professionals Advisory Committee and major payer and hospital groups, such as the Blue Cross Blue Shield Association and the American Hospital Association. Another seat belongs to a representative from an umbrella organization for private insurers, he said.

The panel also includes nonvoting liaisons from CMS, the CDC, and the FDA, giving each agency a platform to provide input and suggestions. Panel meetings are held three times per year to discuss code and RVU changes. Whyte said that meetings are open to any stakeholder and that groups and individuals can request “interested party” status to review applications under consideration by the panel.

Cassidy’s initial letter to the AMA questioned whether this format provides physicians with sufficient input into the code-finalization process. Dissatisfied with Whyte’s response, he now wants more information on how the organization incorporates feedback from all physicians, including a growing percentage of doctors who are opting out of AMA membership.

3. Demands Fee Transparency

Cassidy’s letter this week doubles down on concerns he initially raised in October about the AMA’s control of — and profit from — the CPT code set. Although the codes are often thought of as a billing tool, their reach is broader. The AMA requires that any organization that “uses, references, or displays CPT content” obtain an appropriate license, and codes are updated and published annually.

He questioned how much of the AMA’s “enormous revenue,” including the $513.2 million generated last year, comes from CPT licensing, publications, and related subscriptions.

Cassidy also asked for greater transparency into how costs for CPT access are calculated, noting that licensees often pay a per-user fee, a $1050 annual royalty fee, and a separate $13,000 annual acquisition fee for CPT Link, the software the AMA sells to streamline the integration of CPT codes into workflow systems. The current pricing structure results in higher healthcare costs, Cassidy said, which are “anti-patient and anti-doctor.”

“We respectfully disagree with the characterization that the AMA charges ‘exorbitant fees’ for the use of CPT or that those charges lead to higher healthcare costs,” said Whyte in his letter to Cassidy. Annual CPT license fees are $18.50 per user, with health plans paying $0.24 per member per year for access, he added.

4. Questioned AMA ‘Woke’ Policies

The Louisiana senator’s issues with the AMA extend beyond CPT codes. Cassidy criticized the physician organization in September for what he described as the adoption of increasingly ideological views that advocate “woke policies…inconsistent with many of its members’ views.”

At the time, Cassidy argued that the AMA has taken “policy positions related to gender transitions, abortion, forced diversity, equity, and inclusion (DEI) mandates, and other positions that run contrary to science and ignore the day-to-day issues providers and patients face.” His comments come after President Trump issued an executive order earlier this year that placed more restrictions on gender-affirming care for young patients.

His letter this week revisited those concerns, stating that the AMA’s House of Delegates has repeatedly endorsed policies supporting DEI mandates and gender-transition care. Whyte confirmed in his October response that while the AMA House of Delegates adopts policies that advance diversity in medical education, the AMA “did not directly spend any funds supporting such policy mandates” in 2024.

In addition to his questions about CPT licensing, Cassidy has asked the AMA to explain any partnerships tied to DEI or gender-transition care, how that work is funded, and whether members can opt out of specific advocacy efforts.

5. What Happens Next?

Cassidy has given the AMA until December 15 to respond to his list of questions, promising to utilize other means to secure the requested information from the AMA if they do not voluntarily comply.

https://www.medscape.com/viewarticle/ama-faces-federal-scrutiny-over-cpt-code-revenue-5-things-2025a1000y9k

'WHO Guidance, GLP-1 Price Curbs Unlikely to Change Practice'

 A new World Health Organization (WHO) guideline  recommending GLP-1s for obesity treatment along with recent efforts  to reduce the drugs’ costs are unlikely to change US obesity practice — but actions that change the US healthcare system might, clinicians told Medscape Medical News.

After the two recent and widely heralded events, Medscape Medical News sought feedback from specialists on the potential impacts of the new guideline and price reductions on their practices and patients. While generally appreciating that the guideline helps normalize obesity as a chronic, relapsing disease, our interviewees felt it would have little impact on prescribing the drugs and lifestyle interventions, given the constraints of the US healthcare system. 

While price reductions may give more patients access to GLP-1s, even with the projected reductions, costs will still be out of reach for many patients, they said. And WHO acknowledged  when it released the guideline that “even with rapid expansion in production, GLP-1 therapies are projected to reach fewer than 10% of those who could benefit by 2030.”

Here's how our interviewees reacted to the changes.

Anne Peters, MD, director of the University of Southern California’s Clinical Diabetes Programs, Los Angeles: “The WHO guideline won’t change my practice because I’ve been prescribing GLP-1s for years and I already incorporate a chronic model of care when using these medications in my practice. Patients have frequent follow-up and targeted lifestyle and behavioral interventions. 

“However, a potential benefit of the guideline is it can help take away stigma and bias by defining obesity as a complex chronic disease and stating that the drugs should be available to anybody who has this disease. Now we can say something to patients like, ‘the drug we need to give you is a hormone. Your body is lacking it or lacking receptors or whatever it needs [to work properly], and that’s why we’re prescribing it.’

“When it comes to my prescribing it here, though, we're still slaves to formularies and insurance coverage. I have a friend whose BMI is about 44, and he has heart failure and edema — all reasons to lose weight. But his insurance won't cover the drug to treat his obesity because he doesn't have an indication like fatty liver or sleep apnea. We keep sending him for sleep apnea tests, but he doesn't flunk them because his sleep apnea is mild.

“So, a big barrier to prescribing the newer weight-loss drugs has been the prior authorization process. I've been trying like crazy to help my friend get on Zepbound (tirzepatide). Now that it's cheaper, he can potentially afford to buy it, and that would get him on it. If the barrier of prior authorization didn't exist, or someone can pay out of pocket, then prescribing would be easier for all of us. Nevertheless, many people won’t be able to afford these drugs, even at the reduced prices.”

Sriram Machineni, MD, director of the Fleischer Institute Medical Weight Center at Montefiore Einstein in the Bronx, New York: “I am disappointed by the statement that ‘intensive behavioral interventions’ should be part of the treatment with GLP-1s. The guideline authors did not appear to consider that intensive behavioral therapy is resource-intensive and even in the clinical trial setting, it did not improve outcomes. 

“The term ‘intensive behavioral therapy’ is very specific and should not have been used. Instead, the authors should have outlined the details of the interventions that should be included based on evidence that they change outcomes.

“I was an investigator on the STEP 3 study. The intensive behavioral therapy used in that study was 1000-1200 Kcal a day with meal replacements for 8 weeks followed by 60 weeks of a 1600-1800 Kcal diet, and every 2 weeks one-on-one counseling with the dietitian every 2 weeks with a sole focus on calorie reduction and increasing aerobic physical activity from 100 min a week to 200 min a week.

“Despite all this intensive intervention, the final weight loss in STEP 3 study participants was no better than individuals in the STEP 1 study who did not do an intensive behavioral regimen; instead, they had q 4 week counseling session based on a 500 deficit Kcal diet and were asked to do 150 min of physical activity weekly.

Semaglutide and tirzepatide reduce the appetite so significantly that putting limits on calories to be consumed is meaningless. This is like bariatric surgery and the focus, as per more recent recommendations, is to maintain adequate nutrient intake to prevent vitamin deficiencies; protein intake of 1-1.2 gm /Kg body weight; and perform resistance exercises to maintain muscle and prevent bone and muscle loss. 


“GLP-1 drugs should be used as a part of a program that includes frequent and regular medical follow-up to monitor patients for response and manage side effects; a targeted [not intensive] behavioral intervention to maintain good nutrition despite reduced hunger; increased physical activity, and particularly resistance exercises to keep muscle and bone healthy during treatment.”

Louis J. Aronne, MD, director of the Comprehensive Weight Control Center at Weill Cornell Medicine in New York City: “The WHO recommendations won’t change my perceptions or those of my colleagues at the center, of the drugs' safety, efficacy, and accessibility. But it will change the perceptions of many insurers, employers and providers. The change in prices will definitely have an impact, since the biggest issue we encounter is the inability of our patients to afford the medicine. Right now, the decision of which medicine to prescribe is based primarily on insurance coverage. The price drop will affect our practice as more patients will have access to the medications. I also think insurers and employers who don’t cover the medicines will rethink it, if the cost is lower for them as well. Multiple health problems will improve as a result of treatment. “

Sara Ghoneim, MD, spokesperson for the American Gastroenterological Association and clinical fellow at Massachusetts General Hospital, Boston: “The ‘conditional’ designation is appropriate for the WHO recommendations. We still have gaps in long-term safety data, and from a GI perspective, we're seeing more patients with delayed gastric emptying, nausea, and gastroparesis-like symptoms. The WHO acknowledging these uncertainties while still recommending the drugs reflects a reasonable balance. 

“As a gastroenterologist, I find the emphasis on behavioral therapy as a co-intervention particularly important. These medications work best within a comprehensive care model, not as standalone solutions.

“The price reductions are more likely to change my day-to-day practice than the WHO recommendations. I've had patients who would clearly benefit from GLP-1 therapy but couldn't afford $1000+ monthly out-of-pocket. If we're truly seeing prices drop to $350 or less through direct-to-consumer channels — and eventually Medicare coverage for severe obesity — I'll be discussing these medications with more patients, particularly those with metabolic-associated steatotic liver disease, where we've lacked effective pharmacologic options. 

“While the new pricing agreements help, coverage remains patchy. Patients shouldn't have coverage for diabetes but not for obesity when the metabolic benefits are similar.

“I'm also preparing for increased referrals to manage GI side effects. Gastroparesis symptoms, while usually reversible with dose reduction or discontinuation, still require evaluation. I'm counseling patients proactively about what to watch for and coordinating more closely with endocrinology and primary care. The interdisciplinary approach WHO emphasizes isn't just aspirational — it's practical. Endocrinology, primary care, and gastroenterology should be communicating about these patients, especially as prescriptions increase.”

Amy E. Rothberg, MD, clinical professor of internal medicine and of nutritional sciences at the University of Michigan, Ann Arbor: “The WHO acknowledges that a prescription will not solve the obesity pandemic. Fundamentally, we must address all the social and environmental challenges including, and not least of which, is the food environment and poverty. We need real policy changes to provide equitable access to robust, comprehensive care that is fully reimbursed, and regulations around food marketing, particularly to children.

Medications are only one tool in the toolbox for helping patients manage their obesity. Clinicians should not prescribe a drug in the absence of assessing the patient's lifestyle factors, emotional and psychological status, complicating health conditions, and understanding that obesity is a chronic, relapsing and remitting disease. They also need to ensure that their patients understand that they may need to take the medication lifelong, [and] be willing to provide long-term behavioral and lifestyle counseling or refer to a comprehensive, structured program.”

Hanna Blaney, MD, MPH, assistant professor of medicine and transplant hepatologist, Virginia Commonwealth University, Richmond: “I would like to see further reductions in barriers to accessing appropriate and comprehensive care, including improved coverage of these medications without the need for prior authorization. I would also like to see the development of public health policy to encourage healthy behaviors, with a focus on preventing obesity. I applaud the WHO for publishing this guideline, which cements obesity as a chronic disease requiring treatment and I hope to see improved global access to these life-changing medications.”

Peters serve(d) on the advisory board for: Abbott Diabetes Care; Becton Dickinson; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Lexicon Pharmaceuticals, Inc; Livongo; Medscape; Merck & Co, Inc; Novo Nordisk; Omada Health; OptumHealth; Sanofi; and Zafgen; she received research support from: Dexcom; MannKind Corporation; and AstraZeneca; and serve(d) as a member of a speakers bureau for Novo Nordisk. Machineni reported being involved in semaglutide and tirzepatide clinical trials and being a consultant to Novo Nordisk, Eli Lilly and Company, and Rhythm Pharmaceuticals. Aronne disclosed being a consultant, speaker, and advisor for and receiving research support from Altimmune, Amgen, AstraZeneca, Eli Lilly and Company, IntelliHealth, Janssen, Novo Nordisk, Pfizer, Senda, UnitedHealth Group, Versanis, and others; he has ownership interests in ERX, IntelliHealth, Jamieson, Kallyope, Skye Bioscience, Veru, and others; and he is on the board of directors of ERX, Jamieson Wellness, and IntelliHealth/FlyteHealth; Ghoneim, Rothberg, and Blaney declared no conflicts of interest. 

https://www.medscape.com/viewarticle/who-guidance-glp-1-price-curbs-unlikely-change-practice-2025a1000ybf

Supreme Court Seems Poised To Side With Trump In FTC Firing Case

 by Sam Dorman via The Epoch Times,

The Supreme Court seemed inclined to remove certain limits on President Donald Trump’s power to remove bureaucrats, but oral arguments on Dec. 8 left questions about how far their eventual decision would go in empowering the executive.

The case - Trump v. Slaughter - focused on President Donald Trump’s request to override a legislative barrier to firing members of the Federal Trade Commission (FTC).

Trump attempted to fire Rebecca Slaughter, an FTC commissioner, earlier this year without invoking any of the reasons Congress listed in the FTC Act as valid for removing commissioners such as her.

Slaughter then won multiple court battles in an attempt to stave off that termination.

The Dec. 8 arguments, which lasted more than two hours, could serve as a prelude to much larger changes to the nation’s separation of powers.

Besides Slaughter, other officials could be impacted if the Supreme Court takes up Trump’s invitation to overrule a 90-year precedent called Humphrey’s Executor v. United States.

In that case, a unanimous court said that if agencies exercise “quasi-legislative” or “quasi-judicial” power, their officials may receive extra protection from Congress.

U.S. Solicitor General D. John Sauer opened arguments by telling the court that it should overrule that decision.

Slaughter’s attorney, Amit Agarwal, accused Sauer of suggesting that the federal government has been wrong for decades in creating and blessing independent agencies like the FTC in prior decades.

While some of the justices seemed skeptical of limits that Slaughter attempted to impose on Trump’s executive authority, many of them indicated concern about overruling such a longstanding precedent.

An eventual decision might overrule Humphrey’s Executor or be more limited to Trump’s removal of Slaughter and officials in similar agencies.

Chief Justice John Roberts suggested that a prior case, Seila Law v. Consumer Financial Protection Bureau, had hollowed out the decision in Humphrey’s Executor and indicated that Agarwal should switch to using a different precedent to support his case.

“The one thing Seila Law made pretty clear, I think, is that Humphrey’s Executor is just a dried husk of whatever people used to think it was,” Roberts said.

Justice Sonia Sotomayor told Sauer that he was asking the court to “destroy” the structure of the federal government.

Repeatedly, she pressed him on when the court had overturned such a longstanding and significant precedent.

Justice Brett Kavanaugh similarly asked why no presidents had challenged Humphrey’s view of executive authority for 90 years.

Some of his questioning, however, indicated that he thought predictions of impending chaos were overblown.

Instead, he suggested, ruling in Trump’s favor would entail altering how commissioners are removed rather than invalidating the FTC as a whole.

Kavanaugh also asked Agarwal to address concerns about members of multi-member agencies being insulated from democratic accountability.

Sauer similarly argued “the sky will not fall” if the court limits Congress’s authority.

He pointed to how the court ruled against the protections Congress imposed for the director of the Consumer Financial Protection Bureau in Seila Law.

How the court views Seila Law, decided in 2020, and others could determine how they handle Slaughter’s firing and the president’s removal power more generally.

Justice Amy Coney Barrett told Sauer the court had seen an “eroding of Humphrey’s Executor over the years,” but also indicated concern about how overruling that precedent would impact the structure of government.

Separation of Powers

During oral argument, Roberts seemed sympathetic to the administration’s argument that the modern FTC was very different than the one before the court in Humphrey’s Executor.

In his majority opinion for Seila Law, Roberts had stated in a footnote that the Supreme Court’s “conclusion that the FTC did not exercise executive power has not withstood the test of time.”

Justice Elena Kagan suggested that Sauer was advocating a view of executive power that lacked reasonable limits.

“Once you’re down this road, it’s a little bit hard to see how you stop,” she said, later noting that multiple agencies and lower-level employees could face easier removal.

Many of the justices’ questions wrestled with how best to balance power between Congress and the president. Given the complexity of assessing each agency’s functions, Justice Ketanji Brown Jackson suggested it would be better if Congress were in charge of deciding whether certain positions deserved to have some protection from presidential removal.

By contrast, Justice Clarence Thomas pressed Agarwal on how far Congress could go in limiting presidents’ ability to remove individuals such as heads of the departments of Homeland Security and Commerce.

Justice Neil Gorsuch seemed sympathetic to Sauer’s position. He suggested that the court should go so far as to clarify that Congress cannot delegate its legislative power to the executive branch.

“Is the water warm?” Gorsuch asked.

Separate from whether to overrule Humphrey’s, the court is also considering whether it should rule that judges cannot order the reinstatement of officers removed by the president.

Whatever its decision, the court’s opinion will likely have far-reaching consequences. Multiple legal battles have played out over Trump’s firings of other high-level officials. While the court has offered tentative rulings in those cases, the decision in Slaughter’s case is expected to provide final conclusions of law on this issue.

It’s unclear how this case will impact Trump’s attempt to fire Federal Reserve member Lisa Cook. During oral argument, Sauer indicated her agency may enjoy greater protection and cited recent language the Supreme Court has used in distinguishing the Federal Reserve from other entities.

https://www.zerohedge.com/political/supreme-court-seems-poised-side-trump-ftc-firing-case

DC Police Chief Resigns As 'Massive Scandal' Over Crime Stats Heats Up

 Washington DC Mayor Muriel Bowser announced on Monday that Police Chief Pamela A. Smith will be stepping down, three months after we reported that the DOJ was investigating a "massive scandal" over manipulated crime data.

Smith, who also doesn't know what the term "chain of command" means, is out for unknown reasons - however she told Fox 5 that she resigned to spend more time with her family.

"After 28 years in law enforcement, I have been going nonstop," she said. 

"Serving alongside such dedicated professionals, both those on the front lines and those working tirelessly behind the scenes, has been one of the greatest honors of my career," Smith - who's been on the job just over two years, told the Washington Post

Crime Data Scandal

The DC Police are also under investigation in a pair of federal probes into alleged manipulation of crime statistics. In early September, White House Deputy Chief of Staff Stephen Miller revealed an ongoing Department of Justice (DOJ) investigation into whether Washington D.C. officials manipulated crime statistics is in the process of uncovering a “massive scandal." 

Miller told reporters that when the results of the investigation are finally that, “It will stun you,” adding, “Even though D.C. had the worst crime in America–honestly measured–it dramatically understated how bad it was.”

Miller said that DOJ investigators have uncovered evidence that crime data was manipulated to the point that some murders and homicides were falsely reported as accidents.

The White House Deputy Chief of Staff also assured reporters that the full extent of the manipulation “will be uncovered and it will all be brought to light.”

In Octoberthe Washington Post reported that there was an internal scandal in the DC Police Department- which has been run by Democrats for decades - in which frustrated cops have been talking to the DOJ and have receipts, presented with a bow by D.C. Police Union Chairman Greggory Pemberton. 

WaPo detailed internal accusations that "managers were recording serious crimes as more minor ones to make their police districts appear safer or avoid the ire of top department brass" - and that officers and supervisors 'clashed' over "whether an offense was a robbery or a theft, or whether a weapon used in an assault qualified as potentially deadly."

The frustrated officers "kept lists, documenting cases where they believed a higher-up improperly classified a crime as a lesser offense," with one noting 150 such instances in March of 2024 alone in which staff in the Southeast D.C. police district believed offenses were in appropriately classified. 

"The police department is playing fast and loose with how they report their data so that they can report favorably to the citizens about crime, and I don’t think it’s fair to the city," said Pemberton - who's been assisting the Trump administration and Congressional Republicans with 'information compiled by officers.'

So, a group of pissed off cops within the DC police department have been fighting with superiors and keeping notes over misclassified crimes, and kept notes. Now they're working with the feds to blow the lid. Or as WaPo puts it - "found a receptive audience."

The other investigation is being headed up by the House Oversight Committee with a report expected to be finalized in the coming weeks, according to a committee aide who told WaPo on the condition of anonymity. 

https://www.zerohedge.com/political/dc-police-chief-resigns-massive-scandal-over-crime-stats-heats

When They Say "Democracy", They Don't Mean Democracy

 by James Howard Kunstler,

"Imagine if the US and EU were still aligned on the censorship-by-proxy strategy. Few people realize how close we were to global totalitarianism."

- Michael Shellenberger

Western Civ is choking itself to death with lawfare in the name of “democracy.” If you think just a little bit past the sale, you will realize that few will say what they mean by “democracy,” including the most ardent “democracy” cultists. What it supposedly means is legal outcomes that the political left wants, not what the law, or the truth, or justice requires.

On the surface, the left pretends to want outcomes that favor their roster of designated victim groups: women, dark-skinned people, and sexual outliers, the familiar cast of characters with its tiresome scripts.

But that’s not what they really want.

They don’t really care about the “marginalized.”

What they really want is power.

The “marginalized” are just their clients and shock troops. They want to push everybody around, tell them how to live, and what to think, including the marginalized. If society has to get wrecked in the process, that’s okay — that will just make it easier to “build back better” to their advantage, or so their operating algorithm dictates. The left does not think past its own algorithms.

The “democracy” cultists are foremost against freedom of speech, because speech is what distinguishes human beings among the rest of the animal kingdom, and if you allow it, human beings are liable to develop ideas — ideas being the product of language — and especially ideas that make the “democracy” cultists uncomfortable. For instance, the idea that the “democracy” cultists don’t deserve the power they crave because they are dishonest, unscrupulous, and sadistic. Can’t have people thinking that, or saying it out-loud.

Censorship, the outright suppression of expressed thought, is the primary device for enforcing their version of “democracy.” The “democracy” cultists of the USA were especially avid for it the past decade after Mr. Trump came on the scene and offered to oppose the “democracy” cult’s plans to aggregate power. So, under the catspaw president “Joe Biden,” the FBI, CIA, the State Department’s Global Engagement Center, Stanford University’s Internet Observatory, the social media companies, and the White House itself worked sedulously to suppress the free expression of ideas, including the idea that they were all working to suppress free expression.

When Mr. Trump miraculously survived manifold attempts to stuff him in prison via lawfare and then, attempted murder, and managed to get re-elected, he put an end to the censorship shenanigans in government. That, in turn, became inconvenient to the “democracy” cultists in Europe who were, apparently, not busy enough destroying their own countries’ cultures and their economies. They put extra effort into suppressing free expression among their citizen-subjects: serious jail time for mean texts and mere casual statements on the street.

Now they are coming after the international speech platform “X,” liberated by Elon Musk three years ago at a $44-billion price. The European Commission, a body of unelected bureaucrats under the EU, created a so-called Digital Services Act to deal with the threat of free speech. After a two-year-investigation, the commission has leveled a $140-million fine against “X” for a series of specious offenses, such as not meaningfully verifying account authenticity [blue check marks] eroding trust in verified content. Mr. Musk objected, naturally. Veep JD Vance and Secretary of State Marco Rubio, called it an “attack on American tech.” It’s more than that, of course. It’s an effort to wreck the company, which would eliminate the chief remaining public arena for free speech and genuine news worldwide.

I would expect Mr. Trump to respond shortly, perhaps with tariffs that make it impossible for the Europeans to sell their cars in the USA, or their wine, or whatever else is on offer. He will squeeze them until they drop this stupid crusade to destroy an American company. And then stand by and watch as “democracy” cultists in the USA complain about him defending free speech.

We have enough trouble with the “democracy” cult here at home.

The Norm Eisen Axis-of-Evil has enjoyed endless “funding” from the dark money spigots of George Soros, British hedge fund billionaire Christopher Hohn, and Shanghai-based American billionaire Neville Roy Singham.

Norm Eisen, Lawfare Ninja Supreme

Once the money-flows are turned off, you will see a lot less nuisance litigation aimed at perverting the rule of law and destroying the country. Norm Eisen and his colleagues operate out of a set of foundations and NGOs, chiefly Brookings and the outfit Eisen founded called the States United Democracy Center. They are mere money-launderers.

The federal judiciary is the “democracy” cult’s remaining praetorian guard. The federal judges, especially the Obama and Biden appointed ones, are making sure that Lawfare ninjas won’t be prosecuted for any crimes. The two latest examples: James Comey, case dismissed on procedural issues (for now) on his charge of lying to Congress. And New York AG Leticia James, let off the hook on a mortgage fraud rap by a federal grand jury in the Eastern District of Virginia, probably a case of “jury nullification” and probably due to race — after the fashion of OJ Simpson skating on murder in 1995.

Unfortunately, the remedy of impeaching federal judges is unavailable due to the 60-vote majority required for removal in the Senate. It’s getting to the point where Mr. Trump might have to go medieval on the whole lot of them, declare the Insurrection Act, and move the action into military courts.

Then maybe we’ll see who can handle the truth.

https://www.zerohedge.com/political/when-they-say-democracy-they-dont-mean-democracy

'Dimon claims AI will not cause major job losses next year — as long as it’s properly regulated'

 JPMorgan Chase CEO Jamie Dimon offered an optimistic outlook on artificial intelligence (AI), predicting the technology will not “dramatically reduce” jobs over the next year — provided it is properly regulated.

Dimon was asked by Fox News’ Maria Bartiromo on “Sunday Morning Futures” what Americans should do to prepare for this “new revolution that’s underway with AI,” especially given that the technology is “creating efficiencies to the extent that it is cutting jobs.”

Before answering the question directly, Dimon prefaced his response by noting that jobs and wages had been weakening even before the rise of widespread AI adoption, and that technology is not to blame for that trend.

“Look, I don’t think AI is going to dramatically reduce jobs like unbelievably next year. And for the most part, AI is going to do great stuff for mankind, like tractors did, like fertilizer did, like vaccines did — it’ll save lives,” Dimon said.

“Now, of course, it needs to be properly regulated,” he added. “There are downsides to AI, just like there are to airplanes, pharmaceuticals, cars. All things get used by bad people. So assuming that the government figured out some way to put guardrails around AI… but it will eliminate jobs. It doesn’t mean that people won’t have other jobs.”

Dimon was asked by Fox News’ Maria Bartiromo on “Sunday Morning Futures” what Americans should do to prepare.FOX NEWSThe CEO continued, offering his advice for Americans who may be worried about AI affecting their careers.

“My advice to people would be, you know, critical thinking, learn skills, learn your EQ, learn how to be good in meetings, how to communicate, how to write. You’ll have plenty of jobs and, if it does happen too fast for society, which is possible, you know, we can’t assimilate all those people that quickly,” Dimon said.

According to Dimon, if the government and large corporations are initially unable to make widespread AI adoption work for the public, it’s up to those parties to figure out a plan to phase in the technology “in a way that won’t damage a lot of people.”

The CEO reiterated that while some jobs may be lost to AI, the technology can be used to “retrain people, relocate people,” and provide income assistance or even early retirement.

“The next job may be a better job, but they have to learn how to do the job,” he added, noting again that people with specialized skills will always be valuable.

“It’s going to cause probably more jobs in the short run in total,” he added.

https://nypost.com/2025/12/07/business/jamie-dimon-claims-ai-will-not-cause-major-job-losses-next-year-as-long-as-its-properly-regulated/